These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36358766)

  • 1. Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors.
    Chen KY; Popovic A; Hsiehchen D; Baretti M; Griffith P; Bista R; Baghdadi A; Kamel IR; Simon SM; Migler RD; Yarchoan M
    Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
    Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
    Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study.
    Zhao J; Guo Y; Feng T; Rong D; Kong X; Huang T; Lopez-Lopez V; Yarmohammadi H; Sakamoto Y; Zhu D; Yao A; Xia Y
    J Gastrointest Oncol; 2023 Dec; 14(6):2549-2558. PubMed ID: 38196523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
    Li Y; Liang X; Li H; Chen X
    Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
    Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
    World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment.
    Abu-Sbeih H; Tran CN; Ge PS; Bhutani MS; Alasadi M; Naing A; Jazaeri AA; Wang Y
    J Immunother Cancer; 2019 May; 7(1):118. PubMed ID: 31053161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma.
    Scheiner B; Roessler D; Phen S; Lim M; Pomej K; Pressiani T; Cammarota A; Fründt TW; von Felden J; Schulze K; Himmelsbach V; Finkelmeier F; Deibel A; Siebenhüner AR; Shmanko K; Radu P; Schwacha-Eipper B; Ebert MP; Teufel A; Djanani A; Hucke F; Balcar L; Philipp AB; Hsiehchen D; Venerito M; Sinner F; Trauner M; D'Alessio A; Fulgenzi CAM; Pinato DJ; Peck-Radosavljevic M; Dufour JF; Weinmann A; Kremer AE; Singal AG; De Toni EN; Rimassa L; Pinter M
    JHEP Rep; 2023 Jan; 5(1):100620. PubMed ID: 36578451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Kim JY; Kronbichler A; Eisenhut M; Hong SH; van der Vliet HJ; Kang J; Shin JI; Gamerith G
    Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31731749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
    Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
    Xu S; Lai R; Zhao Q; Zhao P; Zhao R; Guo Z
    Front Immunol; 2021; 12():794099. PubMed ID: 34950153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
    Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
    BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of immune checkpoint inhibitor therapy for advanced lung adenosquamous carcinoma.
    Wei J; Xiang J; Hao Y; Si J; Gu X; Xu M; Song Z
    J Thorac Dis; 2023 Feb; 15(2):260-269. PubMed ID: 36910045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors.
    Xavier CB; Lopes CDH; Awni BM; Campos EF; Alves JPB; Camargo AA; Guardia GDA; Galante PAF; Jardim DL
    Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma.
    Xie F; Chen B; Yang X; Wang H; Zhang G; Wang Y; Wang Y; Zhang N; Xue J; Long J; Li Y; Sun H; Xun Z; Liu K; Chen X; Song Y; Yang X; Lu Z; Mao Y; Sang X; Lu Y; Zhao H
    Front Immunol; 2022; 13():1052937. PubMed ID: 36569829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
    Manca P; Corti F; Intini R; Mazzoli G; Miceli R; Germani MM; Bergamo F; Ambrosini M; Cristarella E; Cerantola R; Boccaccio C; Ricagno G; Ghelardi F; Randon G; Leoncini G; Milione M; Fassan M; Cremolini C; Lonardi S; Pietrantonio F
    Eur J Cancer; 2023 Jul; 187():15-24. PubMed ID: 37099945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals.
    Wang R; Lin N; Mao B; Wu Q
    J Cancer Res Clin Oncol; 2022 May; 148(5):1195-1210. PubMed ID: 34297207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.